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Abstract 
Background: Smoking is a major risk factor for a range of diseases, and quitting smoking provides 
considerable benefits to health. It therefore follows that clinical guidelines on disease management, 
particularly for diseases caused by smoking, should include smoking cessation.  The aim of this study 
was to determine the extent to which this is the case.  
Methods: We conducted a systematic review investigating clinical guidelines and recommendations 
issued by UK national or European transnational medical speciality associations and societies issued 
between 2000 and 2012 on a range of diseases caused by smoking.  We then investigated whether 
selected guidelines contained reference to smoking cessation and smoking cessation advice. 
Results: Although the extent to which smoking and smoking cessation was mentioned in the 
guidelines varied between diseases, only 60% of guidelines identified recognised that smoking is a 
risk factor for the development of the disease and 40% recommended smoking cessation. Only 19% 
of guidelines provided detailed information on how to deliver smoking cessation support. 
Conclusions: Smoking cessation is not comprehensively addressed in current UK and transnational 
European clinical practice guidelines and recommendations. 
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Introduction 
Tobacco use is the biggest cause of preventable morbidity and mortality in the UK1. The diseases it 
causes or exacerbates include cancer, heart disease, lung disease, stroke, peripheral vascular 
disease, diabetes, infection, dementia and macular degeneration2. In addition to premature 
mortality, these diseases cause disability that contributes to social and economic disadvantage3, loss 
of productivity4, and dependence on family or socially-funded carers. The financial cost to society of 
these and other effects of tobacco smoking are estimated to be in excess of £13 billion per annum5. 
This individual and societal burden of disease can be prevented for future generations by preventing 
the uptake of smoking among young people6. However, reducing this burden in the more immediate 
future is dependent upon helping as many current smokers as possible to quit smoking. This is 
particularly relevant to smokers who have already developed a disease caused or exacerbated by 
smoking, since stopping smoking can arrest or in some cases reverse the progression of their 
disease7. It therefore follows that smoking cessation interventions or reference to published 
smoking cessation guidelines should be a key component of the clinical management of these 
diseases, and hence also of published guidelines or their updates on their clinical management.  
We have therefore systematically examined clinical management guidelines produced by 
professional societies and governmental agencies in the UK and Europe for a range of smoking-
related diseases, to assess the extent to which smoking cessation interventions are prioritised within 
them. 
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Methods  
We carried out a series of systematic reviews of clinical guidelines and clinical recommendations 
published since 2000 and produced under the auspices of a relevant UK national or European 
transnational medical speciality association, professional society or government agency, and relating 
to a range of diseases caused or exacerbated by smoking comprising cancer of the lip, oral cavity and 
pharynx, oesophagus, lung, stomach, pancreas, kidney, pelvis or bladder; cardiovascular disease 
(including ischaemic heart disease, angina, myocardial infarction, aortic aneurysms); cerebrovascular 
disease (including stroke, transient ischaemic attack, brain aneurysm); or respiratory disease 
(pneumonia and COPD). We excluded guidelines produced by and for individual European countries 
outside the UK. 
A series of search strategies were developed for two electronic databases (Medline and EMBASE) 
using recognised search filters for identifying clinical guidelines as developed by the Guideline 
Resource Centre8 for each disease. Disease specific terms were developed using the relevant search 
terms as developed by Cochrane Review Groups. Searches were typically conducted to the end of 
2013. We additionally searched the National Library for Health (NLH) Guidelines Finder, the TRIP 
database, and the International Guideline Library. 
We then searched individual guideline documents to establish whether i) smoking was identified as a 
risk factor or major cause of disease; ii) smoking cessation interventions were recommended in 
disease management; and iii) whether there was reference or a link to  specific smoking cessation 
guidelines (for example, the National Institute for Health and Care Excellence guidelines for various 
diseases provide reference to smoking cessation guidelines rather than include specific treatment 
recommendations) or recommendations on evidence-based treatments for smoking cessation, 
including behavioural support and pharmacotherapy, or referral to a stop smoking service.  
The titles, abstracts, and full texts were screened by two reviewers independently to select eligible 
guidelines using previously piloted checklist forms. Disagreements were resolved through discussion 
with a third reviewer. One reviewer extracted data relating to agency responsible for 
developing/issuing guidelines, country of origin, year of publication, status of clinical guidelines (new 
or updated), and level of development (UK/European) using piloted data extraction form. Simple 
descriptive summary statistics are used to report the presence of the smoking cessation advice 
within the guidelines; summaries of these studies are also reported.  
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Results 
Our searches identified 141 eligible clinical guidelines, of which 37 were produced in the UK and 104 
by a European medical speciality association, relevant professional society or government agency. 
Two of the guidelines were included more than once as they had distinct sections on more than one 
eligible cancer under investigation9, 10, thus a total of 144 guidelines were included in the review. Of 
the 144, 86 (60%) referred to smoking as a risk factor for the development of the disease; 57 (40%) 
provided a statement regarding smoking cessation; and 28 (19%) made reference to specific 
treatments for smoking cessation or to a smoking cessation guideline (Table 1). A full list of eligible 
guidelines is provided in Supplementary Table 1 and cessation content by disease broken down as 
follows:  
Table 1 here 
Cancers 
Lip, oral cavity and pharynx cancer 
From 4,452 titles identified in the searches, 46 were selected based on title and abstract. Following 
full text screening, two guidelines, both from the UK, were included11, 12. Both mentioned smoking as 
a risk factor for head and neck cancer and highlighted the importance of smoking cessation, and 
provided details of specific treatments or else referred to a guideline for smoking cessation. 
 
Oesophageal cancer 
From 1,884 titles identified, 22 were selected based on title and abstract and eight included after full 
text screening9, 10, 13-18. Four guidelines were from the UK9, 10, 13, 15 and four were European14, 16-18. Only 
four guidelines (50%), three UK and one European, mentioned smoking as a risk factor for 
oesophageal cancer. All three of these UK guidelines discussed the benefits of smoking cessation9, 13, 
15, but only one provided a link to smoking cessation management guidelines9. 
Lung cancer 
From 4,825 titles identified from the searches, 75 were selected on the basis of titles and abstracts 
and 26 following full text screening19-44, one of which38 was a summary of more extensive guidance 
published by NICE 22, 23, 37, 43. Twenty-one (81%) of these 26 guidelines made reference to the role of 
smoking as a cause of lung cancer19, 20 21-32, 34 35, 37, 40, 42, 43  44; 14 (54%) referred to smoking cessation21-
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23, 26, 30, 32-35, 37, 38, 40, 43, 44, and 4 (15%) provided specific advice or reference to guidelines on smoking 
cessation22, 23, 37, 43. Of these four, three were UK22, 23, 37 and one European-level43 guidelines.   
Gastric cancer 
From 7,259 titles identified from the searches, 34 were selected based on title and abstract and 16 
after full text screening9, 10, 45-58.  Ten of the included guidelines (63%) referred to smoking as a risk 
factor for gastric cancer9, 10, 45-47, 49, 51, 53, 55, 57 but only four (25%; all UK-based) recommended that 
smoking cessation should be advised9, 10, 45, 47, and only one of these provided a link to smoking 
cessation management guidelines9.  
Pancreatic cancer 
From 1,636 titles identified from the searches, 29 were selected on title and abstract and 14 after 
full text screening9, 59-71. Only three (21%; two UK9, 59 and one European71) of these 14 guidelines 
referred to smoking as a risk factor for pancreatic cancer, and one referred to smoking cessation and 
provided a link to smoking cessation management guidelines9.  
Kidney, pelvis and bladder cancer 
From 4,411 titles identified from the searches, 67 were selected based on titles and abstracts and 35 
after full text screening72-106. Nineteen (54%) of these reported that smoking increased the risk of 
disease72, 75, 76, 80, 81, 83, 86-88, 91, 93, 95-102, but only one referred to smoking cessation76 and none included 
any link or recommendation on smoking cessation therapy.  
Cerebrovascular disease 
From 12,414 titles identified, 78 were potentially eligible based on title and abstract and 11 after full 
text screening107-117. Five (36%) of these mentioned smoking as a risk factor for cerebrovascular 
disease110, 111, 116; 6 (55%; 3 UK and 3 European) recommended smoking cessation110, 111, 115, 116; and 
none referred to specific treatments or referenced any smoking cessation guidelines. 
Cardiovascular disease 
From 13,351 titles identified in the searches, 135 were selected based on titles and abstracts and 21 
after full text screening118-138. Of these 21, 13 (62%) reported that smoking increased the risk of 
disease118-120, 122-124, 126, 127, 131, 132, 136, 138, 139; 17 (81%) recommended smoking cessation118, 120-123, 125-128, 
130-132, 134, 136-139; and 13 (62%; 7 UK and 6 European) made reference to specific treatments or 
smoking cessation guidelines118, 120, 122, 125-127, 129, 132, 133, 135-138. 
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Respiratory disease 
From 13,730 hits identified from the searches, 103 were selected based on title and abstract and 11 
after full text screening140-150. Nine (82%) of these mentioned smoking as a risk factor for COPD or 
pneumonia140-144, 146-150; 9 (82%) referred to smoking cessation140-144, 146-149; and 6 (55%; 3 UK and 3 
European) referred to specific treatments or referenced smoking cessation guidelines141-143, 146, 147, 149.  
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Discussion 
Tobacco related diseases, and specifically cardiovascular disease, cancer and COPD, account for 80% 
of deaths in Europe151. Smoking cessation should be a priority in the management of all such 
conditions, and promoted in management guidelines. However, the present paper, which is to our 
knowledge the first systematic review of this, found that 40% of the guidelines we identified did not 
identify smoking as a risk factor for the disease; only 40% recommended smoking cessation in the 
management of the disease; and only 19% provided information on specific smoking cessation 
treatments or else referred to definitive smoking cessation guidance. These findings varied 
substantially between disease categories however, with over half of guidelines on respiratory and 
cardiovascular disease providing smoking cessation guidance, but with much lower proportions 
among cerebrovascular disease and cancer guidelines. UK guidelines were generally more likely to 
include smoking cessation guidance than European guidelines, with the majority citing smoking 
cessation guidance from the NICE152. We acknowledge that not all clinical guidelines for specific 
diseases could include full smoking cessation guidelines, but would expect guidelines on diseases 
caused by smoking to acknowledge and advise on the need to quit smoking. We therefore defined 
reference to existing smoking cessation guidelines where further information could be found as 
sufficient.Smoking cessation increases both quantity and quality of life expectancy at almost any 
age. In respiratory disease, smoking cessation reduces the rate of decline in lung function among 
patients with COPD153; and reduces the risk of lung infections and of asthma exacerbation154. In lung 
cancer, smoking cessation at diagnosis in early stage disease is associated with significantly 
improved survival155. In cardiovascular disease, smoking cessation reduces the risk of recurrence by 
around 50% over the longer term, and in cerebrovascular disease by around 15%156-160. Smoking 
cessation should therefore be a high priority in managing these diseases, and it would therefore be 
reasonable to expect definitive management guidelines to recognize this. Our finding that even in 
respiratory and cardiovascular disease, reference to appropriate smoking cessation guidance or 
provision of specific advice was far from universal indicates that smoking cessation is not receiving 
the attention it merits in the management of these conditions.  
For the less common cancers caused by smoking, such as cancer of the oesophagus, pancreas and 
bladder, inclusion of cessation guidance was generally (with the exception of guidance on cancer of 
the lip, oral cavity or pharynx), even less common. There is evidence that smoking cessation 
improves life expectancy in early stage lung cancer, cardiovascular and respiratory disease154, 155; and 
smoking cessation is likely to have a significant impact in also preventing intercurrent infections161, 
162, promoting wound healing163-165, and other benefits to the management of these conditions. It is 
therefore surprising that smoking cessation is afforded so little priority in the management of these 
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less common cancers. The impact of this omission is likely to be inadequate treatment of tobacco 
addiction, with the consequence of an excess of several hundred thousand preventable deaths and 
significant morbidity. 
Why is this omission so common? There are many potential plausible causes. The authors of these 
guidelines may be experts in specific disease but may not be so knowledgeable in understanding the 
links between tobacco use and disease progression or the benefits of smoking cessation in 
established disease151, 155, 166-168. Authors may also underestimate the strength of tobacco addiction 
169, the difficulty overcoming this addiction170 or may lack the knowledge of the most effective 
methods to achieve smoking cessation171. In addition, authors may be influenced by other barriers 
that effect health professionals discussing smoking cessation with patients such as time, knowledge, 
perceived lack of efficacy or their own use of tobacco172-174. A less benign reason for our findings may 
be the influence of device manufacturers and pharmaceutical companies on guideline production175, 
since disease prevention runs contrary to their commercial interest. Finally, it may be that authors of 
guidelines are focusing on novel procedures or pharmacotherapy and weight these 
recommendations higher than more ‘conservative’ measures despite the effectiveness of the 
latter176. 
We used robust search strategies and screening methods to identify and assess the eligibility of the 
clinical guidelines included in the review; therefore it is unlikely that any guidelines we did not 
identify would have a significant impact on our findings. The indexing of clinical guidelines is still 
being developed; therefore our search strategies were very sensitive and identified many articles 
that were not relevant. Some of the included guidelines were in the form of a very short consensus 
document or a shortened updated guideline; therefore, due to the restrictions on the length of the 
documents it is likely that smoking or smoking cessation may not have been mentioned.  However, if 
the disease is caused by smoking or smoking contributes to its development and smoking cessation 
could reduce risk of the disease or death it should be mentioned in the short versions or updates of 
guidelines, for example, by providing a reference to existing guidelines as often observed in NICE 
guidelines. Our finding that major guidelines on cardiovascular disease, cancer and respiratory 
diseases across Europe neglect smoking prevention is likely to reflect low levels of intervention to 
prevent smoking among people with smoking-related disease, and a consequent failure to avoid 
significant morbidity and mortality. 
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Conclusion 
A plethora of guidelines is produced each year, by a variety of institutions and professional societies 
to disseminate research findings, best practice and to reduce variation in care. Their quality is 
variable, and dissemination and impact of guidelines often poor177. We hope that by drawing 
attention to this deficiency in the inclusion of smoking cessation we can improve this and that this 
will be reflected in changes in clinical practice. For the general standard of smoking cessation advice 
and intervention to be raised, governmental and peer review of practice standards, government 
health policy driving change, smoke-free legislation, commissioning of services and anti-tobacco 
advocacy groups will be needed.  
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Table 1: Summary of clinical guidelines and recommendations with the presence of smoking and 
smoking cessation 
Disease Number of 
guidelines 
included 
Number of guidelines referring to smoking 
Smoking as a 
risk factor 
Smoking 
cessation is 
advised 
Specific treatment/ 
reference to 
guideline is provided 
Cancer     
      Lip, oral cavity & pharynx  2 2  2 2  
      Oesophagus  8 4 3 1  
      Lung  26 21 14 4  
      Gastric 16 10 4 1  
      Pancreas  14 3 1 1 
      Kidney, pelvis & bladder  35 19 1 0 
Cerebrovascular disease  11 5 6 0 
Cardiovascular disease 21 13 17 13 
Respiratory disease 11 9 9 6  
TOTAL 144 86 (60%) 57 (40%) 28(19%) 
Two of the guidelines included more than one cancer under investigation9, 10.  
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Table S1: Characteristics of included studies 
Study (author, year) Disease Recognised body International/Loc
al 
Type of guideline 
Ischemic heart disease & aortic aneurysms 
Secondary Prevention of Coronary Heart 
Disease following Myocardial Infarction: A 
National Clinical Guideline (Scottish 
Intercollegiate Guidelines Network, 2000) 
Coronary heart 
disease/ 
Myocardial 
infarction 
Scottish Intercollegiate Guidelines 
Network (SIGN) 
National Clinical guidelines 
Diagnosis and management of aortic 
dissection (Erbel et al., 2001) 
Aortic dissection European Society of Cardiology International Recommendations 
Management of Stable Angina: A National 
Clinical Guideline (SIGN, 2001) 
Angina SIGN National Clinical guidelines 
Guideline for the management of patients 
with acute coronary syndromes without 
persistent ECG ST segment elevation (British 
Cardiac Society, 2001) 
Acute coronary 
syndrome 
British Cardiac Society Guidelines and 
Medical Practice Committee, and 
Royal College of Physicians Clinical 
Effectiveness and Evaluation Unit 
National Clinical guidelines 
Management of acute coronary syndromes in 
patients presenting without persistent ST-
segment elevation (Bertrand et al., 2002) 
Acute coronary 
syndrome 
European Society of Cardiology International  Task force report/ 
Management strategy 
Management of Stable Angina Pectoris (Fox et 
al., 2006) 
Angina European Society of Cardiology International  Practice guidelines 
Management of Stable Angina: A National Angina SIGN National Clinical guidelines 
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Clinical Guideline (SIGN, 2007) 
Myocardial infarction: Secondary Prevention 
(National Institute for Health and Clinical 
Excellence (NICE), 2007) 
Myocardial 
infarction 
NICE National Clinical guidelines 
Guidelines for the diagnosis and treatment of 
non-ST-segment elevation acute coronary 
syndromes (Bassad et al., 2007) 
Acute coronary 
syndrome  
European Society of Cardiology International Disease management 
guidelines 
Management of Acute Myocardial Infarction 
in patients presenting with ST-segment 
elevation (Vand de Werf et al., 2008) 
Myocardial 
infarction 
European Society of Cardiology International Disease management 
guidelines 
Guidelines on myocardial revascularization 
(Wijns et al., 2010) 
Cardiovascular 
disease 
European Society of Cardiology/ 
European Association for Cardio-
Thoracic Surgery 
International Disease management 
guidelines 
The Management of Stable Angina (NICE, 
2012)  
Angina NICE National Clinical guidelines 
ESC Guidelines for the management of acute 
coronary syndromes in patients presenting 
without persistent ST-segment elevation 
(Hamm et al., 2011) 
Acute coronary 
syndrome 
European Society of Cardiology International Disease management 
guidelines 
Management of abdominal aortic aneurysms 
clinical practice guidelines of the European 
society for vascular surgery (Moll et al., 2011) 
Abdominal aortic 
aneurysms 
European Society of Vascular Surgery International Clinical practice 
guidelines 
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ESC Guidelines for the management of 
acute myocardial infarction in patients 
presenting with ST-segment elevation 
(Steg et al., 2012) 
Myocardial 
infarction 
European Society of Cardiology International Disease management 
guidelines 
European Guidelines on cardiovascular 
disease prevention in clinical practice (version 
2012) (Perk et al., 2012) 
Cardiovascular 
disease 
European Society of Cardiology International Disease management 
guidelines 
Guideline No 93: Acute coronary syndrome 
(SIGN, 2013) 
Acute coronary 
syndrome 
SIGN National Clinical guidelines 
Myocardial infarction: secondary prevention 
(NICE, 2013) 
Myocardial 
infarction 
NICE National Clinical guidelines 
Myocardial infarction with ST-segment 
elevation: the acute management of 
myocardial infarction with ST-segment 
elevation (NICE, 2013) 
Myocardial 
infarction 
NICE National Clinical guidelines 
Myocardial infarction: secondary prevention 
in primary and secondary care for patients 
following a myocardial infarction (partial 
update) (NICE, 2013) 
Myocardial 
infarction 
NICE National Clinical guidelines 
2013 ESC guidelines on the management of 
stable coronary artery disease (Montalescot et 
al., 2013) 
Coronary artery 
disease 
European Society of Cardiology International  Disease management 
guidelines 
Cerebrovascular disease and stroke 
26 
 
European Stroke Initiative (EUSI) 
recommendations for stroke management 
(Hacke et al., 2000) 
Stroke European Stroke Initiative International Disease management 
recommendations 
European Stroke Initiative Recommendations 
for Stroke Management – Update 2003 (Hacke 
et al., 2003) 
Stroke European Stroke Initiative International Disease management 
recommendations 
Management of patients with stroke or TIA: 
Assessment, investigation, immediate 
management and secondary prevention 
(SIGN, 2008) 
Stroke/ Transient 
ischaemic attack 
(TIA) 
SIGN National Clinical guidelines 
Diagnosis and initial management of acute 
stroke and transient ischaemic attack (TIA) 
(NICE, 2008) 
Stroke/ TIA NICE National Clinical guidelines 
ESO Guidelines for management of ischaemic 
stroke and transient ischaemic attack (Ringleb 
et al., 2008) 
Stroke/ TIA European Stroke Organisation International Disease management 
guidelines 
Management of patients with stroke: 
rehabilitation, prevention and management of 
complications, and discharge planning (SIGN, 
2010) 
Stroke SIGN National Clinical guideline 
Diagnosis and initial management of transient 
ischemic attack (Tyrrell et al. 2010) 
TIA Royal College of Physicians (RCP) National Disease management 
recommendations 
27 
 
EFNS guideline on the treatment of cerebral 
venous and sinus thrombosis in adult patients 
(Einhaupl et al., 2010) 
Cerebral 
thrombosis 
European Federation of Neurological 
Societies 
International Disease management 
guidelines 
National clinical guideline for stroke : fourth 
edition (RCP, 2012) 
Stroke RCP National Clinical guideline 
European Stroke Organization guidelines for 
the management of intracranial aneurysms 
and subarachnoid haemorrhage (Steiner et al., 
2013) 
intracranial 
aneurysms/  
subarachnoid 
haemorrhage 
European Stroke Organization National Disease management 
guidelines 
CG162 Stroke rehabilitation: full guideline 
(NICE, 2013) 
Stroke NICE National Rehabilitation 
guidelines 
COPD/ pneumonia 
BTS Guidelines for the Management of 
Community Acquired Pneumonia in Adults 
(British Thoracic Society, 2001) 
Pneumonia British Thoracic Society (BTS)  National Disease management 
guideline 
Guideline 59: Community Management of 
Lower Respiratory Tract Infection in Adults - 
Quick Reference Guide (SIGN, 2002) 
Pneumonia SIGN National Clinical guideline 
Standards for the diagnosis and treatment of 
patients with COPD (ATS/ ERS, 2004) 
COPD American Thoracic Society (ATS)/ 
European Respiratory Society (ERS) 
International Consensus statement 
Standards for the diagnosis and treatment of 
patients with COPD - section for patients (ATS/ 
ERS, 2004) 
COPD ATS/ ERS International Consensus statement 
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Guidelines for the management of adult lower 
respiratory tract infections (Woodhead et al., 
2005) 
Lower respiratory 
tract infection 
ERS International Disease management 
guidelines 
Guidelines for the management of hospital-
acquired pneumonia in the UK (Masterton et 
al., 2008) 
Pneumonia British Society for Antimicrobial 
Chemotherapy 
National Disease management 
guidelines 
Guidelines for the management of community 
acquired pneumonia in adults (Lim et al., 
2009) 
Pneumonia BTS National Disease management 
guidelines 
CG101 Chronic obstructive pulmonary disease 
(update): full guideline (NICE, 2010) 
COPD NICE/ RCP National Clinical guidelines 
Primary care summary of the British Thoracic 
Society guidelines for the management of 
community acquired pneumonia in adults: 
2009 Update (Levy et al., 2010) 
Pneumonia BTS National Disease management 
guidelines 
Global Strategy for the Diagnosis, 
Management, and Prevention of COPD (Global 
Initiative for Chronic Obstructive Lung 
Disease, 2011) 
COPD Global Initiative for Chronic 
Obstructive Lung Disease  
International Strategy 
Guidelines for the management of adult lower 
respiratory tract infections - Full version 
(Woodhead et al., 2011) 
Respiratory tract 
infections 
ERS/  European Society for 
Clinical Microbiology and Infectious 
Diseases 
International Disease management 
guidelines 
Gastric cancer 
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Improving outcomes in Upper Gastro-
Intestinal Cancer (Department of Health, 
2001) 
Upper Gastro-
intestinal cancers 
Department of Health National Guidance for 
commissioning cancer 
services 
Guidelines for the management of 
oesophageal and gastric cancer (Allum et al., 
2002) 
Oesophageal and 
gastric cancer 
Association of Upper Gastrointestinal 
Surgeons of Great Britain and Ireland, 
the British Society of 
Gastroenterology, and the British 
Association of Surgical Oncology 
 
National Clinical practice 
guidelines 
ESMO minimum clinical recommendations for 
diagnosis, treatment and follow-up of gastric 
cancer (Cunningham et al., 2005) 
Gastric cancer European Society for Medical 
Oncology (ESMO) 
International Clinical 
recommendations 
Guideline 87: Management of oesophageal 
and gastric cancer - Full guideline (SIGN, 2006) 
Oesophageal and 
gastric cancer 
SIGN National Clinical guidelines 
Well-differentiated gastric tumors/carcinomas 
(Ruszniewski et al., 2007) 
Gastric cancer European Endocrine Tumor Society International Consensus statement 
Gastric cancer: ESMO clinical 
recommendations for diagnosis, treatment 
and follow-up (Cunningham D., 2007) 
Gastric cancer ESMO International Clinical 
recommendations 
Gastric marginal zone lymphoma of mucosa-
associated lymphoid tissue type: ESMO 
Clinical Recommendations for diagnosis, 
treatment and follow-up (Zucca E., 2007) 
Gastric lymphoma ESMO International Clinical 
recommendations 
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Gastric cancer: ESMO clinical 
recommendations for diagnosis, treatment 
and follow-up (Cunnigham D. & Oliveira J., 
2008) 
Gastric cancer ESMO International Clinical 
recommendations 
Gastric marginal zone lymphoma of MALT 
type: ESMO clinical recommendations for 
diagnosis, treatment and follow-up (Zucca E. & 
Dreyling M., 2008) 
Gastric lymphoma ESMO International Clinical 
recommendations 
Gastric cancer: ESMO Clinical 
Recommendations for diagnosis, treatment 
and follow-up (Jackson et al., 2009) 
Gastric cancer ESMO International Clinical 
recommendations 
Gastric marginal zone lymphoma of MALT 
type: ESMO Clinical Recommendations for 
diagnosis, treatment and follow-up (Zucca E. & 
Dreyling M., 2009) 
Gastric lymphoma ESMO International Clinical 
recommendations 
Gastric cancer: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and 
follow-up (Okines et al., 2010) 
Gastric cancer ESMO International Clinical practice 
guidelines 
Gastric marginal zone lymphoma of MALT 
type: ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up (Zucca E. & 
Dreyling M., 2010) 
Gastric lymphoma ESMO International Clinical practice 
guidelines 
Guidelines for the management of 
oesophageal and gastric cancer (Allum et al., 
Oesophageal and 
gastric cancer 
Association of Upper Gastrointestinal 
Surgeons of Great Britain and Ireland, 
the British Society of 
National Clinical practice 
guidelines 
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2011) Gastroenterology, and the British 
Association of Surgical Oncology 
Gastric cancer: ESMO–ESSO–ESTRO Clinical 
Practice Guidelines for diagnosis, treatment 
and follow-up (Waddell et al., 2013) 
Gastric cancer European Society for Medical 
Oncology/ European Society of 
Surgical Oncology/ European Society 
of Radiotherapy and 
Oncology  
International Disease management 
guidelines 
Gastric marginal zone lymphoma of MALT 
type: ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up (Zucca et 
al., 2013) 
Gastric lymphoma ESMO International Clinical practice 
guidelines 
Lip and oral cavity cancer 
Guideline 90: Diagnosis and management of 
head and neck cancer - Full guideline (SIGN, 
2006) 
Head and neck 
cancer 
SIGN National Clinical guideline 
Head and neck cancer: multidisciplinary 
management guidelines (British Association of 
Otorhinolaryngology, Head and 
Neck Surgery, 2011) 
Head and neck 
cancer 
British Association of 
Otorhinolaryngology, Head and 
Neck Surgery 
National Multidisciplinary 
disease management 
guidelines 
Lung cancer 
ESMO minimum clinical recommendations for 
diagnosis, treatment and follow-up of small-
SCLC ESMO International Clinical 
recommendations 
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cell lung cancer (SCLC) (Felip E., 2001) 
ESMO minimum clinical recommendations for 
diagnosis, treatment and follow-up of non-
small-cell lung cancer (NSCLC) (Felip  E., 2001) 
NSCLC ESMO International Clinical 
recommendations 
Consensus on medical treatment of non-small 
cell lung cancer (Akehurst RL., 2002) 
NSCLS Central European 
Cooperative Oncology Group (CECOG) 
International Consensus statement 
Guideline 80: Management of patients with 
lung cancer - Full guideline (SIGN, 2005) 
Lung cancer SIGN National Clinical guidelines 
Diagnosis and Treatment of Lung Cancer 
(NICE, 2005) 
Lung cancer NICE National Clinical guidelines 
ESMO Minimum Clinical Recommendations 
for diagnosis, treatment and follow-up of 
small-cell lung cancer (SCLC) (Felip et al, 2005) 
SCLC ESMO International Clinical 
recommendations 
ESMO minimum clinical recommendations for 
diagnosis, treatment and follow-up of non-
small-cell lung cancer (NSCLC) (Felip et al., 
2005) 
NSCLC ESMO International Clinical 
recommendations 
Consensus on medical treatment of non-small-
cell lung cancer - Update 2004 (Zielinski et al., 
2005) 
NSCLC CECOG International Consensus/ meeting 
report 
Non-small-cell lung cancer: ESMO clinical 
recommendations for diagnosis, treatment 
NSCLC ESMO International Clinical 
recommendations 
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and follow-up (Besse B., 2007) 
Small-cell lung cancer: ESMO clinical 
recommendations for diagnosis, treatment 
and follow-up (Felip E., 2007) 
SCLC ESMO International Clinical 
recommendations 
Non-small-cell lung cancer: ESMO clinical 
recommendations for diagnosis, treatment 
and follow-up (D'Addario G. & Felip E., 2008) 
NSCLC ESMO International Clinical 
recommendations 
Small-cell lung cancer: ESMO clinical 
recommendations for diagnosis, treatment 
and follow-up (Sørensen M. & Felip E., 2008) 
SCLC ESMO International Clinical 
recommendations 
Non-small-cell lung cancer: ESMO Clinical 
Recommendations for diagnosis, treatment 
and follow-up (D'Addario G. & Felip E. et al., 
2009) 
NSCLC ESMO International Clinical 
recommendations 
Small-cell lung cancer: ESMO clinical 
recommendations for diagnosis, treatment 
and follow-up (Sørensen M. & Felip E., 2009) 
SCLC ESMO International Clinical 
recommendations 
Early-stage and locally advanced (non-
metastatic) non small cell lung cancer ESMO 
Clinical Practice Guidelines for diagnosis, 
treatment and follow-up (Crino et al., 2010) 
NSCLC ESMO International Clinical practice 
guidelines 
Metastatic non-small-cell lung cancer: ESMO 
clinical practice guidelines for diagnosis, 
treatment and follow-up (D'Addario et al., 
NSCLC ESMO International Clinical practice 
guidelines 
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2010 
Small-cell lung cancer: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and 
follow-up (Sørensen M ., et al. 2010) 
SCLC ESMO International Clinical practice 
guidelines 
Neuroendocrine bronchial and thymic 
tumours: ESMO Clinical Practice guidelines for 
diagnosis, treatment and follow-up (Oberg et 
al., 2010) 
Bronchial and 
thymic tumours 
ESMO International Clinical practice 
guidelines 
CG121 Lung cancer: full guideline (NICE, 2011) Lung cancer NICE International Clinical guidelines 
Diagnosis and treatment of lung cancer: 
summary of updated NICE guidance (Baldwin 
et al., 2011) 
Lung cancer NICE International Clinical guidelines 
summary 
1st ESMO Consensus Conference in lung 
cancer; Lugano 2010: small-cell lung cancer 
(Stahel et al., 2011) 
SCLC ESMO International Consensus conference  
Metastatic non-small-cell lung cancer (NSCLC): 
ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up (Peters et 
al., 2012) 
NSCLC ESMO International Clinical practice 
guidelines 
Neuroendocrine bronchial and thymic tumors: 
ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up (Oberg et 
al., 2012) 
Bronchial and 
thymic tumours 
ESMO International Clinical practice 
guidelines 
35 
 
Third CECOG consensus on the systemic 
treatment of non-small-cell lung cancer 
(Brodowicz et al., 2012) 
NSCLC CECOG International Consensus 
Early and locally advanced non-small-cell lung 
cancer (NSCLC): ESMO Clinical Practice 
Guidelines for diagnosis, treatment and 
follow-up (Vansteenkiste et al., 2013) 
NSCLC ESMO International Clinical practice 
guidelines 
Small-cell lung cancer (SCLC): ESMO Clinical 
Practice Guidelines for diagnosis, treatment 
and follow-up (Fruh et al., 2013) 
SCLC ESMO International Clinical practice 
guidelines 
Pancreatic cancer 
Guidelines for the management of patients 
with pancreatic cancer periampullary and 
ampullary carcinomas (Alderson et al., 2005) 
Periampullary and 
ampullary 
carcinomas 
British Society of Gastroenterology, 
Pancreatic Society of Great Britain 
and Ireland, Association of Upper 
Gastrointestinal Surgeons of Great 
Britain and Ireland, Royal 
College of Pathologists 
National Disease management 
guidelines 
ESMO Minimum Clinical Recommendations 
for diagnosis, treatment and follow-up of 
pancreatic cancer (Herrmann et al., 2005) 
Pancreatic cancer ESMO International Clinical 
recommendations 
Well-differentiated pancreatic nonfunctioning 
tumors/carcinoma (Falconi et al., 2006) 
Pancreatic cancer ENETS International Consensus statement 
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Poorly differentiated carcinomas of the 
foregut (gastric, duodenal and pancreatic) 
(Nilsson et al., 2006) 
Carcinomas of 
foregut 
ENETS International Consensus statement 
Gastrinoma (duodenal and pancreatic) (Jensen 
et al., 2006) 
Gastrinoma ENETS International Consensus statement 
Well-differentiated pancreatic 
tumor/carcinoma : insulinoma (de Herder et 
al., 2006) 
Insulinoma ENETS International Consensus statement 
Pancreatic cancer: ESMO clinical 
recommendations for diagnosis, treatment 
and follow-up (Herrmann et al., 2007) 
Pancreatic cancer ESMO International Clinical 
recommendations 
Pancreatic cancer: ESMO clinical 
recommendations for diagnosis, treatment 
and follow-up (Herrmann R. & Jelic S., 2008) 
Pancreatic cancer ESMO International Clinical 
recommendations 
Pancreatic cancer: ESMO Clinical 
Recommendations for diagnosis, treatment 
and follow-up (Cascinu S. &Jelic S., 2009) 
Pancreatic cancer ESMO International Clinical 
recommendations 
Pancreatic cancer: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and 
follow-up (Cascinu et al., 2010) 
Pancreatic cancer ESMO International Clinical practice 
guidelines 
ENETS consensus guidelines for the 
management of patients with digestive 
neuroendocrine neoplasms of the digestive 
system : well-differentiated pancreatic non-
Digestive 
neuroendocrine 
neoplasms 
ENETS International Consensus guidelines 
37 
 
functioning tumors (Falconi et al., 2012) 
ENETS consensus guidelines for the 
management of patients with digestive 
neuroendocrine neoplasms : functional 
pancreatic endocrine tumor syndromes 
(Jensen et al., 20120) 
Digestive 
neuroendocrine 
neoplasms 
ENETS International Consensus guidelines 
Pancreatic adenocarcinoma: ESMO–ESDO 
Clinical Practice Guidelines for diagnosis, 
treatment and follow-up (Seufferlein et al., 
2012) 
Pancreatic 
adenocarcinoma 
ESMO International Clinical practice 
guideline 
Pelvis and bladder cancer 
Guidelines on renal cell cancer (Mickisch et al., 
2002) 
Renal cancer European Association of Urology 
(EAU) 
International Disease management 
guidelines 
Guidelines on bladder cancer (Oosterlinck et 
al., 2002) 
Bladder cancer EAU International Disease management 
guidelines 
ESMO Minimum Clinical Recommendations 
for diagnosis, treatment and follow-up of 
invasive bladder cancer ( Sengeløv L., 2003) 
Bladder cancer ESMO International Clinical 
recommendations 
EAU guidelines on diagnosis and treatment of 
upper urinary tract transitional cell carcinoma 
(Oosterlinck et al., 2004) 
Urinary tract 
carcinoma 
EAU International Disease management 
guidelines 
Guideline 85: Management of transitional cell 
carcinoma of the bladder - Full guideline 
Bladder carcinoma SIGN National Clinical guidelines 
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(SIGN, 2005) 
ESMO Minimum Clinical Recommendations 
for diagnosis, treatment and follow-up of 
invasive bladder cancer (Kataja V. &Pavlidis N., 
2005)  
Bladder cancer ESMO International Clinical 
recommendations 
EAU guidelines on the diagnosis and 
treatment of urothelial carcinoma in situ (van 
der Meijden et al., 2005) 
Urothelial 
carcinoma 
EAU International Disease management 
guidelines 
Invasive bladder cancer: ESMO clinical 
recommendations for diagnosis, treatment 
and follow-up (Bellomnt J. &Albiol S., 2007) 
Bladder cancer ESMO International Clinical 
recommendations 
Renal Cell Carcinoma Guideline (Ljungberg et 
al., 2007) 
Renal carcinoma EAU International Disease management 
guideline 
EAU guidelines on non-muscle-invasive 
urothelial carcinoma of the bladder (Babjuk et 
al., 2008) 
Urothelial 
carcinoma 
EAU International Disease management 
guidelines 
Invasive bladder cancer: ESMO clinical 
recommendations for diagnosis, treatment 
and follow-up (Bellmunt et al., 2008) 
Bladder cancer ESMO International Clinical 
recommendations 
Guidelines on TaT1 (Non-muscle 
invasive) Bladder Cancer (Babjuk et al., 2009) 
Bladder cancer EAU International Disease management 
guidelines 
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Invasive bladder cancer: ESMO clinical 
recommendations for diagnosis, treatment 
and follow-up (Bellmunt et al., 2009) 
Bladder cancer ESMO International Clinical 
recommendations 
Renal cell carcinoma: ESMO clinical 
recommendations for diagnosis, treatment 
and follow-up (Escudier B. & Kataja V., 2009) 
Renal carcinoma ESMO International Clinical 
recommendations 
The updated EAU guidelines on muscle-
invasive and metastatic bladder cancer (Stenzl 
et al., 2009) 
Bladder cancer EAU International Disease management 
guidelines 
Renal Cell Carcinoma (Ljungberg et al., 2010) Renal carcinoma EAU International Disease management 
guidelines 
Non-muscle Invasive Bladder Cancer (Babjuk 
et al., 2010) 
Bladder cancer EAU International Disease management 
guidelines 
Bladder cancer: ESMO Practice Guidelines for 
diagnosis, treatment and follow-up (Bellmunt 
et al., 2010) 
Bladder cancer ESMO International Clinical practice 
guidelines 
Renal cell carcinoma: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and 
follow-up (Escudier B. & Kataja V., 2010) 
Renal carcinoma ESMO International Clinical practice 
guidelines 
Guidelines on Bladder Cancer: Muscle-invasive 
and Metastatic (Stenzl et al., 2010) 
Bladder cancer EAU International Disease management 
guidelines 
Guidelines on upper urinary tract urothelial 
cell carcinoma (Ruopret et al., 2012) 
Urothelial 
carcinoma 
EAU International Disease management 
guidelines 
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Bladder cancer: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and 
follow-up (Bellmunt et al., 2011) 
Bladder cancer ESMO International Clinical practice 
guidelines 
EAU guidelines on non-muscle-invasive 
urothelial carcinoma of the bladder, the 2011 
update (Babjuk et al., 2011) 
Urothelial 
carcinoma 
EAU International Disease management 
guidelines 
Treatment of muscle-invasive and metastatic 
bladder cancer: update of the EAU guidelines 
(Stenzl et al., 2011)  
Bladder cancer EAU International Disease management 
guidelines 
Renal cell carcinoma: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and 
follow-up (Escudier et al., 2012) 
Renal carcinoma ESMO International Clinical practice 
guidelines 
Guidelines on non-muscle invasive bladder 
cancer (TaT1 and CIS) (Babjuk et al., 2012) 
Bladder cancer EAU International Disease management 
guidelines 
Guidelines on Muscle-invasive and Metastatic 
Bladder Cancer (Witjes et al., 2013) 
Bladder cancer EAU International Disease management 
guidelines 
Guidelines on Renal Cell Carcinoma (Ljungberg 
et al., 2013) 
Renal carcinoma EAU International Disease management 
guidelines 
Guidelines on Non-muscle-invasive 
Bladder Cancer (TaT1 and CIS) (Babjuk et al., 
2013) 
Bladder cancer EAU International Disease management 
guidelines 
 Multi-disciplinary Team (MDT) Guidance for 
Managing Renal Cancer (British Association of 
Renal cancer British Association of Urological 
Surgeons Section of Oncology/ British 
National Disease management 
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Urological Surgeons Section of Oncology/ 
British Uro-oncology Group, 2012) 
 
Uro-oncology Group guideline 
Guidelines on Urothelial Carcinomas of the 
Upper Urinary Tract (Roupret et al., 2013) 
Urothelial 
carcinoma 
EAU International Disease management 
guidelines 
ICUD-EAU International Consultation on 
Bladder Cancer 2012: Non-muscle-invasive 
urothelial carcinoma of the bladder (Burger et 
al., 2013) 
Bladder cancer International Consultation on Urologic 
Disease-European Association of 
Urology (ICUD-EAU) 
International International 
consultation 
EAU Guidelines on Primary Urethral 
Carcinoma (Gakis et al., 2013) 
Urethral carcinoma EAU International Disease management 
guidelines 
ICUD-EAU International Consultation on 
Bladder Cancer 2012: Urothelial carcinoma of 
the prostate (Palou et al., 2013) 
Urothelial 
carcinoma 
ICUD-EAU International International 
consultation 
ICUD-EAU International Consultation on 
Bladder Cancer 2012: Chemotherapy for 
urothelial carcinoma-neoadjuvant and 
adjuvant settings (Sternberg et al., 2013) 
Urothelial 
carcinoma 
ICUD-EAU International International 
consultation 
Oesophageal cancer 
Guidelines for the management of 
oesophageal and gastric cancer (Allum et al., 
2002) 
Oesophageal and 
gastric cancer 
Association of 
Upper Gastrointestinal Surgeons of 
Great Britain and Ireland/  British 
Society of 
National Disease management 
guidelines 
42 
 
Gastroenterology/ British Association 
of Surgical Oncology 
ESMO Minimal Clinical Recommendations for 
diagnosis, treatment and follow-up of 
esophageal cancer (Stahl et al., 2005) 
Oesophageal 
cancer 
ESMO International Clinical 
recommendations 
Management of oesophageal and gastric 
cancer: A national clinical guideline (SIGN, 
2006) 
Oesophageal and 
gastric cancer 
SIGN National Clinical guidelines 
Esophageal cancer: ESMO clinical 
recommendations for diagnosis, treatment 
and follow-up (Stahl M.  & Oliveira J., 2008) 
Oesophageal 
cancer 
ESMO International Clinical 
recommendations 
Esophageal cancer: ESMO Clinical 
Recommendations for diagnosis, treatment 
and follow-up (Stahl M.  & Oliveira J., 2009) 
Oesophageal 
cancer 
ESMO International Clinical 
recommendations 
Esophageal cancer: Clinical Practice Guidelines 
for diagnosis, treatment and follow-up (Stahl 
et al., 2010) 
Oesophageal 
cancer 
ESMO International Clinical practice 
guidelines 
Guidelines for the management of 
oesophageal and gastric cancer (Allum et al., 
2011) 
Oesophageal and 
gastric cancer 
Association of Upper 
Gastrointestinal Surgeons of Great 
Britain and Ireland/ British Society of 
Gastroenterology/ British Association 
of Surgical Oncology 
National Disease management 
guideline 
 
